The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India (DCGI) for the Intranasal Covid-19 vaccine. Read more on Dynamite News:
The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials of intranasal vaccine BBV154.
The World Health Organisation (WHO) on Wednesday granted approval for Emergency Use Listing (EUL) for Bharat Biotech’s COVID-19 vaccine, Covaxin. Full story
Vaccine maker Bharat Biotech on Wednesday said the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of its COVID-19 vaccine Covaxin up to 12 months from the date of manufacture.
Bharat Biotech’s COVID-19 vaccine Covaxin has shown less reduction in ‘neutralizing activity’ while comparing with Delta and Delta AY.1 (Delta plus) variants in those who are fully vaccinated with the vaccine according to a study by the Indian Council of Medical Research-National Institute of Virology (NIV).
Trials for Bharat Biotech’s Covid-19 vaccine Covaxin on children are underway and results are expected to be released by September, All India Institute of Medical Sciences (AIIMS) director Randeep Guleria informed.
The Union Health Ministry on Wednesday said that new born calf serum is not an ingredient of the final Covaxin vaccine by Bharat Biotech.
Indigenously-developed Covid-19 vaccine Covaxin, made by Bharat Biotech, neutralises multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well, the Indian Council of Medical Research (ICMR) said on Wednesday. Full details on Dynamite News.
Prime Minister Narendra Modi on Monday took the first dose of Covaxin, India’s homegrown coronavirus vaccine developed by biotechnology firm Bharat Biotech and Indian Council of Medical Research, addressing the hesitancy over the COVID-19 vaccine.
English
English
English
